In a report published Friday, Jefferies reiterated its Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX ), but lowered its price target from $103.00 to $96.00. Jefferies noted, “ONXX reported in-line Q4 Kyprolis sales while guiding to higher 2013 OpEx on PIII expenses and full-year of Kyprolis mktg. Notably, management's commentary